CGEN
Compugen LtdstockNASDAQ
compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen's wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.96 | 2026-11-06 | +7.14% | 2.951 |
| 1M | 1.98 | 2026-10-13 | +6.06% | 1.906 |
| 3M | 2.41 | 2026-08-13 | -12.86% | 1.379 |
| 6M | 2.85 | 2026-05-13 | -26.32% | 1.448 |
| 1Y | 1.65 | 2025-11-13 | +27.27% | 1.551 |
| 2Y | 1.59 | 2024-11-13 | +32.08% | — |
| 5Y | 5.87 | 2021-11-12 | -64.22% | 1.633 |
Compugen Ltd (NASDAQ:CGEN) stock price today is $2.10, and today's volume is 209,644. CGEN is down 0.943% today. The 30 day average volume is 229,425. CGEN market cap is $198.93M with 94.73M shares outstanding.
